Going Public -“We still believe we’re an undiscovered gem” Charting the Future of Immune Tolerance: Insights from the CEO of TOPAS

22 November 2024 │ Topas in the News

Interview between Hugo Fry, Chief Executive Officer at Topas Therapeutics and Urs Moesenfechtel, Editorial Director of GoingPublic

Go to Article